Browse News
Filter News
Found 772,099 articles
-
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
5/29/2023
Harbour BioMed announced the results of phase Ib clinical trial of porustobart, in combination of toripalimab in patients with hepatocellular carcinoma were released at the American Society of Clinical Oncology Annual Meeting 2023.
-
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
5/29/2023
Hummingbird Bioscience announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology Annual Meeting being held 2-6 June, 2023 in Chicago.
-
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
5/29/2023
Amplia Therapeutics Limited is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in combination with FOLFIRINOX treatment.
-
Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models
5/29/2023
RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
-
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
5/28/2023
Abbisko Therapeutics Co., Ltd. announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib in treating patients with advanced tenosynovial giant cell tumor, will be released at the 2023 American Society of Clinical Oncology annual meeting to be held in Chicago, USA from June 2 to June 6, 2023.
-
Bristol Myers Squibb’s Reblozyl induced nearly twice the red blood cell transfusion independence compared with the current standard treatment epoetin alfa for lower-risk myelodysplastic syndrome.
-
The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.
-
The New York–based biotech will present data from a Phase I trial of 98 patients showing that fianlimab combined with Libtayo led to an overall response rate of 61% in advanced melanoma.
-
Biological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions
5/26/2023
Biological Dynamics announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.
-
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
5/26/2023
Ferring Pharmaceuticals announced that its clinical development partner, Seikagaku Corporation, achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation.
-
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
5/26/2023
Marinus Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of ZTALMY® oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two to 17 years of age.
-
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable NSCLC at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
5/26/2023
Bristol Myers Squibb announced that the CHMP of the EMA has recommended approval of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.
-
Schrödinger to Present at Jefferies Global Biopharma Conference
5/26/2023
Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.
-
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
5/26/2023
Ipsen announced that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Products for Human Use of the European Medicines Agency confirms the negative opinion given in January 2023.
-
Guardant Health to Participate in Upcoming June 2023 Investor Conferences
5/26/2023
Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.
-
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
5/26/2023
Takeda announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology being held June 2-6, 2023, in Chicago, Ill.
-
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology
5/26/2023
Invitae, a leading medical genetics company, announced nine studies to be presented at the 2023 American Society of Clinical Oncology Annual Meeting held in Chicago from June 2-6, 2023.
-
City of Hope researchers will present new treatments for blood, prostate and other cancers at 2023 American Society of Clinical Oncology Annual Meeting
5/26/2023
City of Hope announced it would present research on promising treatments for blood, prostate and other cancers, as well as studies on germline testing for hereditary cancers and on reducing heart disease in childhood cancer survivors, at the 2023 American Society of Clinical Oncology's annual conference from June 2 to 6 in Chicago.
-
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
5/26/2023
ProfoundBio announced that dosing in the Phase 1/2 first-in-human trial of PRO1160 has initiated in the US, and the company received approval from National Medical Products Administration to initiate the PRO1160 trial in China.
-
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
5/26/2023
Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.